Skip to main content

Advertisement

SpringerLink
Log in

Conceptual Structure-Based Drug Design and Discovering of Novel Inhibitors of Norepinephrine Transporter (NET) as Potential Antipsychotic Agents for Mental Disorder

  • Original Article
  • Published:
Chemistry Africa Aims and scope Submit manuscript

Abstract

The inhibition of norepinephrine transporter (NET) plays an important role in the treatment of a psychiatric disorder. The present work employed a fast, simple, accurate and cost-effective cheminformatics approach using computer-aided structured-based drug design (SBDD) technique to complement our previous study. From our previous work, compound 2 was selected as the template compound for the design because of its better biological activity, lied within the applicability domain of the developed model and above all, it possessed good pharmacological attributes. As a consequence, Ten (10) hypothetical compounds were designed with better pharmacological properties as potential antipsychotic agents when compared the results with a standard drug (Atomoxetine). All the designed compounds displayed optimal molecular interactions with significant binding affinities (ranges from − 7.2 to − 7.6 kcal/mol) toward the active site of the biological target.  Besides, all the designed compounds possessed a higher number of hydrogen bonds which could be linked to the structural modification and incorporation of electrophilic substituents (NH2, –OH, –OCH3, –CH3, NO2, –CF3, –F and –Cl) at different positions in the pharmacophore of the template compound compared to the standard drug with a lower binding affinity of − 6.1 kcal/mol. An outstanding molecular interaction was observed in the designed compound 2i among the selected compounds which could be attributed to the presence of two strongly activating substituents (–OH and −OCH3) at the ortho and meta positions in the pharmacophore (–Chlorophenyl) of the compound. Similarly, drug-likeness and bioavailability assessments revealed that none of the designed compounds including the standard drug violates the criteria stipulated by Lipinski’s rule of five. Likewise, the ADMET/Pharmacokinetics investigations showed that all the designed compounds possessed outstanding pharmacological properties, good oral bioavailability, excellent human gastrointestinal absorption a remarkable blood–brain barrier (BBB) permeability evidenced from the BOILED Egg graphics. More so, toxicity evaluation of the selected compounds showed that all the selected compounds are non-AMES mutagenicity and non-carcinogenicity. Interestingly, none of the selected compounds portend to be a human ether-a-go-go-related gene (hERG) cardiovascular toxicity. Hence, it is envisaged that the present study would serve as a promising prototype for further in vivo and experimental investigations in the discovery and development of more potent antipsychotic drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Babatunde S, Adamu O, Gideon U, Sani S (2020) QSAR modeling, molecular docking and ADMET/pharmacokinetic studies: a chemometrics approach to search for novel inhibitors of norepinephrine transporter as potent antipsychotic drugs. J Iran Chem Soc 17(8):1953–1966

    Article  Google Scholar 

  2. Dessalew N (2009) QSAR study on dual SET and NET reuptake inhibitors: an insight into the structural requirement for antidepressant activity. J Enzyme Inhib Med Chem 24(1):262–271

    Article  CAS  Google Scholar 

  3. Peruskovi’c DS, Stevanovi’c NR, Loli’c AD, Nikoli’c MR, Baosi’c RM (2014) Quantitative structure-activity relationship study of some antipsychotics by multiple linear regressions. Am J Anal Chem 5:335–342

    Article  Google Scholar 

  4. Kapur S, Agid O, Mizrahi R, Li M (2006) How antipsychotics work—from receptors to reality. NeuroRx 3(1):10–21

    Article  Google Scholar 

  5. Olasupo SB, Uzairu A, Shallangwa G, Uba S (2019) QSAR analysis and molecular docking simulation of norepinephrine transporter (NET) inhibitors as anti-psychotic therapeutic agents. Heliyon 5(10):e02640

    Article  Google Scholar 

  6. Schlessinger A et al (2011) Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci 108(38):15810–15815

    Article  CAS  Google Scholar 

  7. Olasupo SB, Uzairu A, Adamu GS, Uba S (2020) Computational modeling and pharmacokinetics/ADMET study of some arylpiperazine derivatives as novel antipsychotic agents targeting depression. Chem Afr 1–10. https://doi.org/10.1007/s42250-020-00161-4

  8. Bhat S, Newman AH, Freissmuth M (2019) How to rescue misfolded SERT, DAT and NET: targeting conformational intermediates with atypical inhibitors and partial releasers. Biochem Soc Trans 47(3):861–874

    Article  CAS  Google Scholar 

  9. Tareq Hassan Khan M (2010) Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr Drug Metab 11(4):285–295

    Article  Google Scholar 

  10. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1–3):3–25

    Article  CAS  Google Scholar 

  11. Andricopulo AD, Salum LB, Abraham DJ (2009) Structure-based drug design strategies in medicinal chemistry. Curr Top Med Chem 9(9):771–790

    Article  CAS  Google Scholar 

  12. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD (2015) Molecular docking and structure-based drug design strategies. Molecules 20(7):13384–13421

    Article  CAS  Google Scholar 

  13. Andersen J, Ringsted KB, Bang-Andersen B, Strømgaard K, Kristensen AS (2015) Binding site residues control inhibitor selectivity in the human norepinephrine transporter but not in the human dopamine transporter. Sci Rep 5:15650

    Article  CAS  Google Scholar 

  14. Ounthaisong U, Tangyuenyongwatana P (2017) Cross docking study of flavanoids against tyrosinase enzymes using PyRx 0.8 virtual screening tool. TJPS 41

  15. Daina A, Zoete V (2016) A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 11(11):1117–1121

    Article  CAS  Google Scholar 

  16. Yang H et al (2019) admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics 35(6):1067–1069

    Article  CAS  Google Scholar 

  17. Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717

    Article  Google Scholar 

  18. Rawn JD, Ouellette RJ (2018) Organic chemistry: structure, mechanism, synthesis. Academic Press, Cambridge

    Google Scholar 

  19. Aswathy L, Jisha RS, Masand VH, Gajbhiye JM, Shibi IG (2018) Design of novel amyloid β aggregation inhibitors using QSAR, pharmacophore modeling, molecular docking and ADME prediction. In Silico Pharmacol 6(1):12

    Article  Google Scholar 

  20. Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK (2010) Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. PLoS One 5(8):e12029

    Article  Google Scholar 

  21. Adeniji SE, Arthur DE, Abdullahi M, Haruna A (2020) Quantitative structure–activity relationship model, molecular docking simulation and computational design of some novel compounds against DNA gyrase receptor. Chem Afr 3(2):391–408

    Article  CAS  Google Scholar 

  22. Lipinski CA (2016) Rule of five in 2015 and beyond: target and ligand structural limitations, ligand chemistry structure and drug discovery project decisions. Adv Drug Deliv Rev 101:34–41

    Article  CAS  Google Scholar 

  23. Qian S-B, Waldron L, Choudhary N, Klevit RE, Chazin WJ, Patterson C (2009) Engineering a ubiquitin ligase reveals conformational flexibility required for ubiquitin transfer. J Biol Chem 284(39):26797–26802

    Article  CAS  Google Scholar 

  24. Huang C, Zheng C, Li Y, Wang Y, Lu A, Yang L (2014) Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 15(5):710–733

    Article  Google Scholar 

  25. Broccatelli F et al (2011) A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J Med Chem 54(6):1740–1751

    Article  CAS  Google Scholar 

  26. Chen L, Li Y, Zhao Q, Peng H, Hou T (2011) ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques. Mol Pharm 8(3):889–900

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We wish to acknowledge members of the theoretical and physical chemistry group, the chemistry department, Ahmadu Bello University Zaria. We sincerely appreciate David Arthur, Abdulateef Jimoh, Abdulfatai Usman and Jonh Philip Ameji for their technical support and advice in the course of this study.

Funding

The authors received no direct funding for this study.

Author information

Authors and Affiliations

  1. National Agency for Food and Drug Administration and Control (NAFDAC), Abuja, Nigeria

    Sabitu Babatunde Olasupo

  2. Department of Chemistry, Ahmadu Bello University, Zaria, Nigeria

    Adamu Uzairu, Gideon Adamu Shallangwa & Sani Uba

Authors
  1. Sabitu Babatunde Olasupo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adamu Uzairu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gideon Adamu Shallangwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sani Uba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabitu Babatunde Olasupo.

Ethics declarations

Conflict of Interest

The authors pronounced they have no conflict of interest.

Ethical approval

This article does not contain any studies with human or animal subjects.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Olasupo, S.B., Uzairu, A., Shallangwa, G. et al. Conceptual Structure-Based Drug Design and Discovering of Novel Inhibitors of Norepinephrine Transporter (NET) as Potential Antipsychotic Agents for Mental Disorder. Chemistry Africa 4, 115–125 (2021). https://doi.org/10.1007/s42250-020-00208-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42250-020-00208-6

Keywords

Search

Navigation